Increased Cancer Risk & Effectiveness Concerns Prompt EU-Wide Review Of Preterm Birth Medicine

The European Medicines Agency is re-examining the benefits and risks of hydroxyprogesterone medicines for gynecologic and obstetrical conditions at the request of the French regulator ANSM.

Premature newborn baby girl in the hospital incubator after c-section in 33 week
Hydroxyprogesterone caproate is given to prevent pregnancy loss or premature birth • Source: Shutterstock

The European Medicines Agency has commenced an EU-wide review of medicines containing hydroxyprogesterone after two recent studies raised concerns about their safety and effectiveness.

These medicines, available as hydroxyprogesterone caproate, are given as injections to prevent pregnancy loss or premature birth in pregnant women....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography